OpenAI says it will buy Orchestra Bio to add AI tools for drug research.
NoteBy OossaPublished by Oossa: Last updated: 1 min read
OpenAI announced it will acquire Orchestra Bio. The deal aims to put AI into life‑science research labs. OpenAI says the move will help biopharma teams speed up drug development and create new treatments. No financial terms were disclosed.
Biotech firms could use OpenAI’s models to cut the time needed to test drug candidates.
Research
Microsoft says its Diagnostic Orchestrator beat physicians on past medical cases, but the system has not been tested in real clinical care.
Research
OpenAI shared a formal‑verification draft of a Navier‑Stokes solution in September, but experts say it diverges from the claimed approach and its contribution is unclear.
Research
In a test of routine theoretical-physics calculations, GPT-6-Astra got 49 of 50 answers right with web search, at a reported average cost of $2.40 per problem.
Oossa · Newsletter
The week in AI, explained
Every Monday: the stories worth knowing, in plain language. Free, no spam.
